Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:TMBR

Timber Pharmaceuticals (TMBR) Stock Price, News & Analysis

Timber Pharmaceuticals logo

About Timber Pharmaceuticals Stock (NYSE:TMBR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.34
$2.94
52-Week Range
N/A
Volume
26,307 shs
Average Volume
511,937 shs
Market Capitalization
$1.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

Receive TMBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TMBR Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Timber Pharmaceuticals Inc (TMBRQ)
See More Headlines

TMBR Stock Analysis - Frequently Asked Questions

Timber Pharmaceuticals shares reverse split on the morning of Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Timber Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Castor Maritime (CTRM) and Phunware (PHUN).

Company Calendar

Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:TMBR
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Price / Cash Flow
N/A
Book Value
$1.79 per share
Price / Book
N/A

Miscellaneous

Free Float
3,378,000
Market Cap
$1.21 million
Optionable
Not Optionable
Beta
0.03
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:TMBR) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners